ATE519782T1 - Peptide und ihre verwendung zur behandlung von hiv infektionen - Google Patents

Peptide und ihre verwendung zur behandlung von hiv infektionen

Info

Publication number: ATE519782T1
Authority: AT; Austria
Prior art keywords: amino acid; phenylalanine; cysteine; acid; alanine
Prior art date: 2002-12-19

Application number

AT03813584T

Other languages

English (en)

Inventor

Knut Adermann

Frank Kirchhoff

Jan Muench

Axel Schulz

Wolf-Georg Forssmann

Original Assignee

Ipf Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-19

Filing date

2003-12-19

Publication date

2011-08-15

2003-12-19 Application filed by Ipf Pharmaceuticals Gmbh filed Critical Ipf Pharmaceuticals Gmbh

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE519782T1 publication Critical patent/ATE519782T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
208000031886 HIV Infections Diseases 0.000 title 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 7
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 7
235000008729 phenylalanine Nutrition 0.000 abstract 7
150000001413 amino acids Chemical group 0.000 abstract 6
235000018417 cysteine Nutrition 0.000 abstract 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 6
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 5
235000004279 alanine Nutrition 0.000 abstract 5
235000001014 amino acid Nutrition 0.000 abstract 5
229940024606 amino acid Drugs 0.000 abstract 5
125000003118 aryl group Chemical group 0.000 abstract 5
230000002209 hydrophobic effect Effects 0.000 abstract 4
BWKMGYQJPOAASG-SECBINFHSA-N D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-SECBINFHSA-N 0.000 abstract 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
239000004471 Glycine Substances 0.000 abstract 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 3
235000013922 glutamic acid Nutrition 0.000 abstract 3
239000004220 glutamic acid Chemical group 0.000 abstract 3
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical group OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 2
229930182820 D-proline Chemical group 0.000 abstract 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
125000000539 amino acid group Chemical group 0.000 abstract 2
235000003704 aspartic acid Nutrition 0.000 abstract 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 2
230000037430 deletion Effects 0.000 abstract 2
238000012217 deletion Methods 0.000 abstract 2
229960000310 isoleucine Drugs 0.000 abstract 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 2
235000014705 isoleucine Nutrition 0.000 abstract 2
235000018977 lysine Nutrition 0.000 abstract 2
239000004474 valine Substances 0.000 abstract 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
235000009582 asparagine Nutrition 0.000 abstract 1
229960001230 asparagine Drugs 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
229930182817 methionine Chemical group 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT03813584T 2002-12-19 2003-12-19 Peptide und ihre verwendung zur behandlung von hiv infektionen ATE519782T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02028465		2002-12-19
PCT/EP2003/014654 WO2004056871A2 (en)	2002-12-19	2003-12-19	Peptides and their use for the treatment of hiv infections

Publications (1)

Publication Number	Publication Date
ATE519782T1 true ATE519782T1 (de)	2011-08-15

Family

ID=32668727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03813584T ATE519782T1 (de)	2002-12-19	2003-12-19	Peptide und ihre verwendung zur behandlung von hiv infektionen

Country Status (8)

Country	Link
US (1)	US7655629B2 (de)
EP (1)	EP1572743B1 (de)
JP (1)	JP4505336B2 (de)
AT (1)	ATE519782T1 (de)
AU (1)	AU2003303218A1 (de)
CA (1)	CA2509423A1 (de)
ES (1)	ES2369771T3 (de)
WO (1)	WO2004056871A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100210528A1 (en) *	1999-03-05	2010-08-19	Leland Shapiro	Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20100144630A1 (en) *	1999-03-05	2010-06-10	Leland Shapiro	Compositions, methods and uses for inhibition and/or treatment of influenza infection
AP2081A (en) *	2004-06-18	2010-01-04	Ipf Pharmaceuticals Gmbh	Oligomeric peptides and their use for the treatment of HIV infections
CA2626675A1 (en) *	2005-11-02	2007-05-18	Ambrx, Inc.	Biosynthetic polypeptide fusion inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0616614A1 (de)	1991-04-18	1994-09-28	The Uab Research Foundation	Zusammensetzungen und methoden zur inhibition von elastase
US5972901A (en) *	1994-03-23	1999-10-26	Case Western Reserve University	Serpin enzyme complex receptor--mediated gene transfer
US6296164B1 (en)	1999-07-13	2001-10-02	Dale Medical Products, Inc.	Medical device holder
CA2391348A1 (en)	1999-07-29	2001-02-08	Assem Ziady	Enhanced delivery via serpin enzyme complex receptor
ES2307549T3 (es)	1999-11-08	2008-12-01	Ipf Pharmaceuticals Gmbh	Peptido inhibidor del virus circulante humano (virip) y su uso.

2003
- 2003-12-19 CA CA002509423A patent/CA2509423A1/en not_active Abandoned
- 2003-12-19 EP EP03813584A patent/EP1572743B1/de not_active Expired - Lifetime
- 2003-12-19 AT AT03813584T patent/ATE519782T1/de active
- 2003-12-19 JP JP2004561391A patent/JP4505336B2/ja not_active Expired - Fee Related
- 2003-12-19 AU AU2003303218A patent/AU2003303218A1/en not_active Abandoned
- 2003-12-19 WO PCT/EP2003/014654 patent/WO2004056871A2/en not_active Ceased
- 2003-12-19 ES ES03813584T patent/ES2369771T3/es not_active Expired - Lifetime
- 2003-12-19 US US10/539,627 patent/US7655629B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1572743A2 (de)	2005-09-14
JP4505336B2 (ja)	2010-07-21
US20070072805A1 (en)	2007-03-29
ES2369771T3 (es)	2011-12-05
AU2003303218A8 (en)	2004-07-14
JP2006522584A (ja)	2006-10-05
CA2509423A1 (en)	2004-07-08
WO2004056871A2 (en)	2004-07-08
EP1572743B1 (de)	2011-08-10
AU2003303218A1 (en)	2004-07-14
US7655629B2 (en)	2010-02-02
WO2004056871A3 (en)	2004-10-21

Legal Events

Date

Code

Title

Description

2012-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1572743

Country of ref document: EP

Publication	Publication Date	Title
NO20070296L (no)	2007-02-27	Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner
ATE368053T1 (de)	2007-08-15	Antimikrobielle peptide
DK1531791T3 (da)	2010-11-01	Forebyggelse og begrænsning af iskæmi
ATE164852T1 (de)	1998-04-15	Glp-1-analoga verwendbar in der diabetesbehandlung
MXPA04000597A (es)	2004-04-20	Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
FR2766191B1 (fr)	2000-11-10	Peptides anti-microbiens de crustaces
DE60228136D1 (de)	2008-09-18	Cytokin-proteinfamilie
WO2005123771B1 (en)	2006-04-27	Oligomeric peptides and their use for the treatment of hiv infections
DE69840024D1 (de)	2008-10-30	Antimikrobielle Peptide, abstammend von Ubiquicidin
WO2004014937A3 (en)	2005-02-17	Thrombin peptide derivatives
DE602004028266D1 (de)	2010-09-02	Angiogene peptide und ihre verwendungen
AU2003303218A8 (en)	2004-07-14	Peptides and their use for the treatment of hiv infections
CY1109946T1 (el)	2014-09-10	Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
DE69935414D1 (en)	2007-04-19	Humanes btrcp protein
ATE245168T1 (de)	2003-08-15	Peptide, die anti-zellanhaftungsaktivität aufweisen
DK1504036T3 (da)	2011-10-24	Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
DE60313970D1 (de)	2007-07-05	Lineare kationische peptide mit fungizider wirksamkeit
DE69117965D1 (de)	1996-04-18	Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper
SE9700301D0 (sv)	1997-01-31	New compound
ATE411812T1 (de)	2008-11-15	Peptide zur behandlung von infektionen mit dem herpes-virus
EP0361956A3 (de)	1991-07-10	Expression von rekombinanten Proteinen mit niedrigem Molekulargewicht
EA200401611A1 (ru)	2005-12-29	Пептиды gp41 и способы ингибирования слияния вич с клетками-мишенями на их основе
WO2005094870A3 (en)	2006-03-16	Use of osteopontin fragment svvglr-derived peptides for the treatment of ischemic diseases
WO2002083729A3 (en)	2003-07-31	Polypeptides derived from amyloid precursor peptide (app) and their uses
DE50310131D1 (de)	2008-08-21	Peptide mit hohem cysteingehalt